GI Oncology Year in Review: Metastatic Pancreatic Cancer - NAPOLI-3 and JACOG1611

Forgot your password?

Select specialty

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

By Yale Cancer Center FEATURING Jill Lacy

March 14, 2024

Integrity CE

M. Pishvaian

2024 ESMO Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub

Integrity CE

2024 ASCO® Annual Meeting Insights Hub

Yale Cancer Center

Hani Babiker

Aditya Shreenivas

S. Chakrabarti

Integrity CE

2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub

Insights from 2024 ESMO GI Annual Meeting

T. Seufferlein

Yale Cancer Center

Integrity CE

J. Hernandez

2024 ASCO® Annual Meeting Insights Hub

T. Macarulla

Insights from 2023 ASCO® Annual Meeting

Y. Janjigian, S. Cytryn, S. Maron

Fred Hutchinson Cancer Center

Login

Login

Join VuMedi

GI Oncology Year in Review: Metastatic Pancreatic Cancer - NAPOLI-3 and JACOG1611

Hypothetical Patient Case: Hepatocellular Carcinoma with Progression…

Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and …

Related Videos

How Recent Data Impacts Pancreatic Cancer Management

ESMO 2024 Summary: Updates in Pancreatic Cancer and Impacts on Pract…

ASCO® 2024 Insights: "The GIANT Trial (EA2186) - Gem & nab-Paclitaxe…

Debates in Neoadjuvant Therapy in Resectable Pancreatic Cancer: Why …

Updates in Perioperative Therapy of Pancreatic Cancer

ASCO® 2024 Summary: "Advancing GI Cancer Treatment - The Clinical Ut…

NORPACT-1 Trial Updates: Neoadjuvant FOLFIRINOX vs. Upfront Surgery …

Clinical Takeaways in From Recent Key Trials in Pancreatic Cancer

Neoadjuvant IO in MSI-High GI Cancers: Special Focus on the DREAM GI…

Debates in Neoadjuvant Therapy in Resectable Pancreatic Cancer: Why …

ASCO® 2024 Insights: "Biomarker-Directed Treatment for Pancreatic Ad…

ASCO® 2024 Insights: "Summary of the PASS-01 Trial - 1L FOLFIRINOX v…

ASCO® 2024 Insights: "EXPEL-PANC - A Ph2 Study of BXCL701 + Pembro i…

ESMO GI 2024 Insights: Role of Personalized Medicine in Pancreatic C…

GI Oncology Year in Review: Precision Medicine Update in Metastatic …

Perspectives on the Recent FDA Approval of NALIRIFOX in Frontline Me…

Updates in Nonmetastatic Upper-GI Adenocarcinoma

ASCO® 2024 Insights: "Efficacy, Safety, and PD of CM24 With Nivo & C…

ASCO® 2023 Summary: "GI Expert Panel Discussion on Key Trials Includ…

Precision Medicine in GI Cancers